Evolving role of entrectinib in treatment of NTRK -positive tumors
Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2021-08, Vol.17 (22), p.2835-2846 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2846 |
|---|---|
| container_issue | 22 |
| container_start_page | 2835 |
| container_title | Future oncology (London, England) |
| container_volume | 17 |
| creator | Chawla, Neal Bui, Nam Q Seetharam, Mahesh |
| description | Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with
fusion positive solid tumors and
positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated. |
| doi_str_mv | 10.2217/fon-2020-0936 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2518741669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2518741669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-ac36c5bc24f131e1a98f704ae3779dcedbaf36025f016204ee4e8bb2ec8630a93</originalsourceid><addsrcrecordid>eNo9kEtLAzEURoMotlaXbmWWbqJ5TTJZaqkPLApS1yGT3khkZlKTacF_7wytru7r8ME9CF1ScsMYVbc-dpgRRjDRXB6hKVVC4IoTejz0QmkspRYTdJbzFyFC8ZKcognnlZaMySm6X-xiswvdZ5FiA0X0BXR9AteHLtRF6IphsH07LMfb6-r9pcCbmEMfdlD02zamfI5OvG0yXBzqDH08LFbzJ7x8e3ye3y2xY5r32DouXVk7JjzlFKjVlVdEWOBK6bWDdW09l4SVnlDJiAAQUNU1A1dJTqzmM3S9z92k-L2F3Js2ZAdNYzuI22xYSSsl6PDvgOI96lLMOYE3mxRam34MJWbUZgZtZtRmRm0Df3WI3tYtrP_pP0_8F0QUaGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2518741669</pqid></control><display><type>article</type><title>Evolving role of entrectinib in treatment of NTRK -positive tumors</title><source>MEDLINE</source><source>PubMed Central</source><creator>Chawla, Neal ; Bui, Nam Q ; Seetharam, Mahesh</creator><creatorcontrib>Chawla, Neal ; Bui, Nam Q ; Seetharam, Mahesh</creatorcontrib><description>Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with
fusion positive solid tumors and
positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-0936</identifier><identifier>PMID: 33896226</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Benzamides - pharmacology ; Benzamides - therapeutic use ; Cell Line, Tumor ; Clinical Trials as Topic ; Disease Models, Animal ; Drug Approval ; Drug Evaluation, Preclinical ; Humans ; Indazoles - pharmacology ; Indazoles - therapeutic use ; Membrane Glycoproteins - antagonists & inhibitors ; Membrane Glycoproteins - genetics ; Molecular Targeted Therapy - methods ; Molecular Targeted Therapy - trends ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - mortality ; Neoplasms - pathology ; Oncogene Proteins, Fusion - antagonists & inhibitors ; Oncogene Proteins, Fusion - genetics ; Progression-Free Survival ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Pyrazoles - pharmacology ; Pyrazoles - therapeutic use ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Receptor, trkA - antagonists & inhibitors ; Receptor, trkA - genetics ; Receptor, trkB - antagonists & inhibitors ; Receptor, trkB - genetics ; Receptor, trkC - antagonists & inhibitors ; Receptor, trkC - genetics</subject><ispartof>Future oncology (London, England), 2021-08, Vol.17 (22), p.2835-2846</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c293t-ac36c5bc24f131e1a98f704ae3779dcedbaf36025f016204ee4e8bb2ec8630a93</citedby><cites>FETCH-LOGICAL-c293t-ac36c5bc24f131e1a98f704ae3779dcedbaf36025f016204ee4e8bb2ec8630a93</cites><orcidid>0000-0001-5350-7583 ; 0000-0001-9201-6840 ; 0000-0001-7863-7958</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33896226$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chawla, Neal</creatorcontrib><creatorcontrib>Bui, Nam Q</creatorcontrib><creatorcontrib>Seetharam, Mahesh</creatorcontrib><title>Evolving role of entrectinib in treatment of NTRK -positive tumors</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with
fusion positive solid tumors and
positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.</description><subject>Animals</subject><subject>Benzamides - pharmacology</subject><subject>Benzamides - therapeutic use</subject><subject>Cell Line, Tumor</subject><subject>Clinical Trials as Topic</subject><subject>Disease Models, Animal</subject><subject>Drug Approval</subject><subject>Drug Evaluation, Preclinical</subject><subject>Humans</subject><subject>Indazoles - pharmacology</subject><subject>Indazoles - therapeutic use</subject><subject>Membrane Glycoproteins - antagonists & inhibitors</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Molecular Targeted Therapy - trends</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - pathology</subject><subject>Oncogene Proteins, Fusion - antagonists & inhibitors</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Progression-Free Survival</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Receptor, trkA - antagonists & inhibitors</subject><subject>Receptor, trkA - genetics</subject><subject>Receptor, trkB - antagonists & inhibitors</subject><subject>Receptor, trkB - genetics</subject><subject>Receptor, trkC - antagonists & inhibitors</subject><subject>Receptor, trkC - genetics</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLAzEURoMotlaXbmWWbqJ5TTJZaqkPLApS1yGT3khkZlKTacF_7wytru7r8ME9CF1ScsMYVbc-dpgRRjDRXB6hKVVC4IoTejz0QmkspRYTdJbzFyFC8ZKcognnlZaMySm6X-xiswvdZ5FiA0X0BXR9AteHLtRF6IphsH07LMfb6-r9pcCbmEMfdlD02zamfI5OvG0yXBzqDH08LFbzJ7x8e3ye3y2xY5r32DouXVk7JjzlFKjVlVdEWOBK6bWDdW09l4SVnlDJiAAQUNU1A1dJTqzmM3S9z92k-L2F3Js2ZAdNYzuI22xYSSsl6PDvgOI96lLMOYE3mxRam34MJWbUZgZtZtRmRm0Df3WI3tYtrP_pP0_8F0QUaGA</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Chawla, Neal</creator><creator>Bui, Nam Q</creator><creator>Seetharam, Mahesh</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5350-7583</orcidid><orcidid>https://orcid.org/0000-0001-9201-6840</orcidid><orcidid>https://orcid.org/0000-0001-7863-7958</orcidid></search><sort><creationdate>20210801</creationdate><title>Evolving role of entrectinib in treatment of NTRK -positive tumors</title><author>Chawla, Neal ; Bui, Nam Q ; Seetharam, Mahesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-ac36c5bc24f131e1a98f704ae3779dcedbaf36025f016204ee4e8bb2ec8630a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Benzamides - pharmacology</topic><topic>Benzamides - therapeutic use</topic><topic>Cell Line, Tumor</topic><topic>Clinical Trials as Topic</topic><topic>Disease Models, Animal</topic><topic>Drug Approval</topic><topic>Drug Evaluation, Preclinical</topic><topic>Humans</topic><topic>Indazoles - pharmacology</topic><topic>Indazoles - therapeutic use</topic><topic>Membrane Glycoproteins - antagonists & inhibitors</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Molecular Targeted Therapy - trends</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - pathology</topic><topic>Oncogene Proteins, Fusion - antagonists & inhibitors</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Progression-Free Survival</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Receptor, trkA - antagonists & inhibitors</topic><topic>Receptor, trkA - genetics</topic><topic>Receptor, trkB - antagonists & inhibitors</topic><topic>Receptor, trkB - genetics</topic><topic>Receptor, trkC - antagonists & inhibitors</topic><topic>Receptor, trkC - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chawla, Neal</creatorcontrib><creatorcontrib>Bui, Nam Q</creatorcontrib><creatorcontrib>Seetharam, Mahesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chawla, Neal</au><au>Bui, Nam Q</au><au>Seetharam, Mahesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolving role of entrectinib in treatment of NTRK -positive tumors</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>17</volume><issue>22</issue><spage>2835</spage><epage>2846</epage><pages>2835-2846</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with
fusion positive solid tumors and
positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.</abstract><cop>England</cop><pmid>33896226</pmid><doi>10.2217/fon-2020-0936</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-5350-7583</orcidid><orcidid>https://orcid.org/0000-0001-9201-6840</orcidid><orcidid>https://orcid.org/0000-0001-7863-7958</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2021-08, Vol.17 (22), p.2835-2846 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2518741669 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Benzamides - pharmacology Benzamides - therapeutic use Cell Line, Tumor Clinical Trials as Topic Disease Models, Animal Drug Approval Drug Evaluation, Preclinical Humans Indazoles - pharmacology Indazoles - therapeutic use Membrane Glycoproteins - antagonists & inhibitors Membrane Glycoproteins - genetics Molecular Targeted Therapy - methods Molecular Targeted Therapy - trends Neoplasms - drug therapy Neoplasms - genetics Neoplasms - mortality Neoplasms - pathology Oncogene Proteins, Fusion - antagonists & inhibitors Oncogene Proteins, Fusion - genetics Progression-Free Survival Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyrazoles - pharmacology Pyrazoles - therapeutic use Pyrimidines - pharmacology Pyrimidines - therapeutic use Receptor, trkA - antagonists & inhibitors Receptor, trkA - genetics Receptor, trkB - antagonists & inhibitors Receptor, trkB - genetics Receptor, trkC - antagonists & inhibitors Receptor, trkC - genetics |
| title | Evolving role of entrectinib in treatment of NTRK -positive tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A47%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolving%20role%20of%20entrectinib%20in%20treatment%20of%20NTRK%20-positive%20tumors&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Chawla,%20Neal&rft.date=2021-08-01&rft.volume=17&rft.issue=22&rft.spage=2835&rft.epage=2846&rft.pages=2835-2846&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-0936&rft_dat=%3Cproquest_cross%3E2518741669%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2518741669&rft_id=info:pmid/33896226&rfr_iscdi=true |